Enlight Medical Technologies (Shenzhen) Co., Ltd.

Enlight Medical Technologies is a global medical technology company headquartered in Boston, Massachusetts, with research and development centers and manufacturing facilities in Boston, San Francisco, Shanghai, Beijing, and Shenzhen. The company specializes in interventional medical devices for structural heart disease, vascular intervention, and neuromodulation products. The company's core therapeutic areas include: (1) valve intervention—addressing mitral regurgitation and other valvular pathologies through catheterization-based approaches; (2) aortic and peripheral intervention—treating aortic dissection and peripheral vascular disease; (3) neuromodulation—using electrode stimulation for Parkinson's disease, epilepsy, chronic pain, and urinary incontinence; and (4) brain-computer interface (BCI) technology for neurological applications and functional enhancement. The company also develops life science and diagnostic platforms, including proteomic analysis tools aligned with the Human Protein Atlas initiative. Enlight Medical maintains GMP-certified manufacturing facilities and operates across both passive and active device platforms with AI imaging capabilities. The company holds multiple medical device licenses in China and has multiple advanced clinical-stage or submitted products. Research and development teams have 15+ years of medical device engineering and production management experience. The company was founded in Boston and has expanded significantly in China, serving structural heart disease and neuromodulation markets. As of 2023, a spinoff entity (Yinghe Brain Science) completed a Series A funding round focused on next-generation neuromodulation and BCI technology development.